Biocept Company Profile (NASDAQ:BIOC)

About Biocept

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIOC
  • CUSIP:
Key Metrics:
  • Previous Close: $2.13
  • 50 Day Moving Average: $1.72
  • 200 Day Moving Average: $1.35
  • 52-Week Range: $0.74 - $5.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.34
  • P/E Growth: -0.02
  • Market Cap: $37.27M
  • Outstanding Shares: 17,499,000
  • Beta: 2.65
Profitability:
  • Net Margins: -876.22%
  • Return on Equity: -764.73%
  • Return on Assets: -279.58%
Debt:
  • Debt-to-Equity Ratio: -0.47%
  • Current Ratio: 0.35%
  • Quick Ratio: 0.25%
Additional Links:
Companies Related to Biocept:

Analyst Ratings

Consensus Ratings for Biocept (NASDAQ:BIOC) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.90 (10.80% downside)

Analysts' Ratings History for Biocept (NASDAQ:BIOC)
Show:
DateFirmActionRatingPrice TargetDetails
11/10/2016Feltl & Co.UpgradeHold -> Buy$2.00View Rating Details
8/31/2016Rodman & RenshawSet Price TargetBuy$2.50View Rating Details
6/6/2016Roth CapitalInitiated CoverageBuy$1.20View Rating Details
1/10/2016HC WainwrightReiterated RatingBuy$4.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Biocept (NASDAQ:BIOC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/9/2016Q316($0.57)($0.57)$1.05 millionViewListenView Earnings Details
8/2/2016Q216($0.22)($0.20)ViewN/AView Earnings Details
5/12/2016Q116($0.23)($0.25)ViewListenView Earnings Details
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.24)$165.00 millionViewN/AView Earnings Details
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details
5/12/2015Q115($0.61)($0.37)ViewListenView Earnings Details
3/9/2015Q414($0.88)($0.87)ViewN/AView Earnings Details
11/13/2014($0.82)($0.87)ViewN/AView Earnings Details
8/15/2014($0.67)($0.67)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biocept (NASDAQ:BIOC)
Current Year EPS Consensus Estimate: $0.40 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.22)($0.22)($0.22)
Q3 20162($0.65)($0.18)($0.42)
Q4 20162($0.35)($0.18)($0.27)
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Biocept (NASDAQ:BIOC)
Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 2.84%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2016Claire ReissMajor ShareholderBuy227,272$1.10$249,999.20View SEC Filing  
10/19/2016David F. HaleDirectorBuy90,909$1.10$99,999.90View SEC Filing  
10/19/2016Lyle J. ArnoldSVPBuy45,000$1.10$49,500.00View SEC Filing  
10/19/2016Timothy KennedyCFOBuy36,363$1.10$39,999.30View SEC Filing  
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.00View SEC Filing  
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Biocept (NASDAQ:BIOC)
DateHeadline
News IconBiocept, Inc. (NASDAQ:BIOC) Daily Sentiment Score At 0.352 - Stock Observer (NASDAQ:BIOC)
www.thestockobserver.com - February 23 at 3:22 PM
News IconEarnings Guidance on Biocept, Inc.(BIOC) - Energy Index (NASDAQ:BIOC)
www.energyindexwatch.com - February 23 at 3:22 PM
prnewswire.com logoBiocept to Release 2016 Fourth Quarter and Full Year Financial ... - PR Newswire (press release) (NASDAQ:BIOC)
www.prnewswire.com - February 21 at 3:24 PM
News IconStock On Watchlist: Biocept, Inc. (NASDAQ:BIOC) Price Target ... - Rockville Register (NASDAQ:BIOC)
rockvilleregister.com - February 21 at 10:41 AM
finance.yahoo.com logoBiocept to Release 2016 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 7, 2017 (NASDAQ:BIOC)
finance.yahoo.com - February 21 at 10:41 AM
News IconGlobal Circulating Biomarkers Market in 2020: Accurate Understanding of Patient’s Prognosis Proves Vital to Growth (NASDAQ:BIOC)
reports.pr-inside.com - February 20 at 10:54 AM
News IconBiocept Inc BIOC Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:BIOC)
www.bioportfolio.com - February 18 at 3:48 PM
News IconBiocept, Inc. (NASDAQ:BIOC) Daily Sentiment Score At 0.685 - Stock Observer (NASDAQ:BIOC)
www.thestockobserver.com - February 17 at 3:31 PM
News IconBiocept, Inc. (BIOC): Essential Chart Information - NY Stock News (NASDAQ:BIOC)
nystocknews.com - February 17 at 3:31 PM
News IconRecent Report Covers Upcoming Opportunities in Cell-Free DNA Testing Market (NASDAQ:BIOC)
reports.pr-inside.com - February 17 at 10:37 AM
News IconWhich insiders are buying Biocept, Inc. (BIOC)? | Post Analyst - Post Analyst (NASDAQ:BIOC)
postanalyst.com - February 16 at 5:32 AM
prnewswire.com logoBiocept Appoints Michael Terry Senior Vice President Commercial Operations - PR Newswire (press release) (NASDAQ:BIOC)
www.prnewswire.com - February 16 at 5:32 AM
finance.yahoo.com logoBiocept Appoints Michael Terry Senior Vice President Commercial Operations (NASDAQ:BIOC)
finance.yahoo.com - February 16 at 5:32 AM
sbwire.com logoCell-Free DNA (CfDNA) Testing Market Up to 2024; Regional Markets, Technology Developments, Types, Applications, and the Competitive Landscape (NASDAQ:BIOC)
www.sbwire.com - February 14 at 9:29 PM
News IconConsensus Notes on Biocept, Inc. (NASDAQ:BIOC) - Rockville Register (NASDAQ:BIOC)
rockvilleregister.com - February 14 at 4:28 PM
sbwire.com logoGlobal Liquid Biopsy Market Projected to Expand at a CAGR of 21.7% by 2026 End (NASDAQ:BIOC)
www.sbwire.com - February 14 at 2:25 AM
News IconBiocept, Inc. (BIOC) Sees Significant Increase in Short Interest (NASDAQ:BIOC)
xboxonezone.com - February 13 at 4:24 PM
streetinsider.com logoBiocept (BIOC) Releases CEO Letter to Stockholders (NASDAQ:BIOC)
www.streetinsider.com - February 11 at 3:56 PM
News IconBiocept Inc (NASDAQ:BIOC) CEO Releases Shareholders Letter (NASDAQ:BIOC)
wallstreetpr.com - February 11 at 3:56 PM
prnewswire.com logoBiocept's CEO Issues Letter to Stockholders - PR Newswire (press release) (NASDAQ:BIOC)
www.prnewswire.com - February 10 at 8:25 PM
News IconAn End-of-Day Technical Review: Biocept, Inc. (BIOC), Jaguar Animal Health, Inc. (JAGX) - Post Analyst (NASDAQ:BIOC)
postanalyst.com - February 10 at 3:24 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Sears, Mead Johnson, Activision, Biocept - Nasdaq (NASDAQ:BIOC)
www.nasdaq.com - February 10 at 3:24 PM
News IconBiocept, Inc. (Nasdaq: BIOC) Shares Respond Aggressively to News - StockNewsUnion (NASDAQ:BIOC)
stocknewsunion.com - February 10 at 3:24 PM
News IconPharmAthene, Inc. (NYSE:PIP)- Most Active Trio on Investment Estimation: Biocept, Inc. (NASDAQ:BIOC) - Street Wise Report (press release) (blog) (NASDAQ:BIOC)
streetwisereport.com - February 10 at 2:08 AM
News IconGlobal Circulating Tumor Cells Market Analysis, Size, Share, Trends and Forecast by 2024 – Orbis Research (NASDAQ:BIOC)
www.usfinancialnewstoday.com - February 9 at 4:04 PM
finance.yahoo.com logoBiocept's CEO Issues Letter to Stockholders (NASDAQ:BIOC)
finance.yahoo.com - February 9 at 4:04 PM
finance.yahoo.com logo8:06 am Biocept CEO issues letter to shareholders outling priorities for 2017 (NASDAQ:BIOC)
finance.yahoo.com - February 9 at 4:04 PM
biz.yahoo.com logoBIOCEPT INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BIOC)
biz.yahoo.com - February 9 at 4:04 PM
News IconLiquid Biopsy Market to expand at a CAGR of 21.7% through 2016 to 2026 (NASDAQ:BIOC)
reports.pr-inside.com - February 9 at 2:08 AM
News IconQuarterly EPS Of Biocept, Inc. (NASDAQ:BIOC) Set At $-0.185 ... - Stock Observer (NASDAQ:BIOC)
www.thestockobserver.com - February 8 at 4:04 PM
sg.finance.yahoo.com logoGSK warns profits to be hit by generic drugs competition (NASDAQ:BIOC)
sg.finance.yahoo.com - February 8 at 4:04 PM
finance.yahoo.com logoBiocept to Present at the 19th Annual BIO CEO and Investor Conference (NASDAQ:BIOC)
finance.yahoo.com - February 6 at 3:56 PM
News IconThe Top 100 Developers Of Cancer In-Vitro Diagnostics Tests (NASDAQ:BIOC)
www.rnrmarketresearch.com - February 6 at 2:00 AM
News IconBiocept, Inc. (NASDAQ:BIOC) Daily Sentiment Score At 0.041 - Stock Observer (NASDAQ:BIOC)
www.thestockobserver.com - February 3 at 9:03 PM
News IconLiquid Biopsy Products Market to Record an Impressive Growth Rate During Forecast 2024 (NASDAQ:BIOC)
www.medgadget.com - January 31 at 9:12 PM
News IconQuarterly EPS Of Biocept, Inc. (NASDAQ:BIOC) Set At $-0.185 - Stock Observer (NASDAQ:BIOC)
www.thestockobserver.com - January 31 at 4:10 PM
News IconIs the Needle Ready to Move on Biocept, Inc. (NASDAQ:BIOC) - Prospect Journal (NASDAQ:BIOC)
prospectjournal.com - January 30 at 8:47 PM
News IconShares of Biocept, Inc. (NASDAQ:BIOC) Advance After Release of ... - Nelson Research (NASDAQ:BIOC)
nelsonobserver.com - January 30 at 3:46 PM
News IconWhat is the Street Saying About Biocept, Inc. (NASDAQ:BIOC)? - Aiken Advocate (NASDAQ:BIOC)
aikenadvocate.com - January 27 at 3:57 PM
News IconHigh Volatility Creating Buzz Mid-Session For Biocept, Inc. (NASDAQ:BIOC) - Wall Street Beacon (NASDAQ:BIOC)
wsbeacon.com - January 27 at 3:57 PM
News IconGlobal Circulating Tumor Cells Market Forecasts Report 2015-2022 (NASDAQ:BIOC)
www.medgadget.com - January 27 at 2:35 AM
News IconStock Seesawing as Volatility Sweeps in on Biocept, Inc. (NASDAQ:BIOC) - Wall Street Beacon (NASDAQ:BIOC)
wsbeacon.com - January 26 at 9:35 PM
News IconJust the Facts on Biocept Inc (BIOC) - StockNewsJournal (NASDAQ:BIOC)
stocknewsjournal.com - January 26 at 4:34 PM
News IconBiocept, Inc. (NASDAQ:BIOC) Analytical Analysis - The Newburgh Press (NASDAQ:BIOC)
newburghpress.com - January 26 at 2:32 AM
4-traders.com logoBIOCEPT INC : Other Events (form 8-K) (NASDAQ:BIOC)
www.4-traders.com - January 25 at 9:31 PM
News IconStocks Turns on Analysts Forecast: Exelixis, Inc. (NASDAQ:EXEL ... - Street Wise Report (press release) (blog) (NASDAQ:BIOC)
streetwisereport.com - January 25 at 4:24 PM
News IconEnlivened Volatility Spotted in Shares of Biocept, Inc. (NASDAQ:BIOC) - Wall Street Beacon (NASDAQ:BIOC)
wsbeacon.com - January 25 at 4:24 PM
marketexclusive.com logoBIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Other Events - Market Exclusive (NASDAQ:BIOC)
marketexclusive.com - January 25 at 4:24 PM
biz.yahoo.com logoBIOCEPT INC Files SEC form 8-K, Other Events (NASDAQ:BIOC)
biz.yahoo.com - January 25 at 4:24 PM
4-traders.com logoNovadaq Technologies : How These Medical Research Stocks are Faring? -- Quintiles IMS, OpGen, Novadaq Technologies, and Biocept (NASDAQ:BIOC)
www.4-traders.com - January 24 at 4:27 PM

Social

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Where is Biocept's stock going? Where will Biocept's stock price be in 2017?

3 brokers have issued 12-month target prices for Biocept's shares. Their predictions range from $1.20 to $2.50. On average, they expect Biocept's stock price to reach $1.90 in the next year.

When will Biocept announce their earnings?

Biocept is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

How do I buy Biocept stock?

Shares of Biocept can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Biocept stock cost?

One share of Biocept stock can currently be purchased for approximately $2.13.

Biocept (NASDAQ:BIOC) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Biocept (NASDAQ:BIOC)

Earnings History Chart

Earnings by Quarter for Biocept (NASDAQ:BIOC)

Dividend History Chart

Dividend Payments by Quarter for Biocept (NASDAQ:BIOC)

Last Updated on 2/24/2017 by MarketBeat.com Staff